NEW YORK (GenomeWeb) – Veracyte announced today that it has priced a public offering of 5 million shares of its common stock at $6 per share, for gross proceeds of $30 million.

The offering’s underwriters have also been granted a 30-day option to buy an additional 750,000 shares at the public offering price, minus underwriting discounts and commissions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.